Testosterone therapy for men: what the TRAVERSE trial actually settled about safety

Testosterone replacement therapy for men with clinically documented low testosterone — hypogonadism confirmed through symptoms and repeated blood testing, not simply an age-related decline within normal range — had prescribing rates depressed for years by cardiovascular safety concerns raised in earlier, smaller observational studies. The TRAVERSE trial, a large, dedicated prospective safety study specifically designed to resolve that question, found that properly managed testosterone therapy in hypogonadal men did not increase the risk of major adverse cardiovascular events compared to placebo — a genuinely significant finding given how long the earlier safety uncertainty had shaped clinical caution and FDA labeling around the therapy.

That result has meaningfully changed prescribing patterns — rates have risen substantially since, particularly among men in their 30s to 50s, and regulatory warnings tied to the earlier cardiovascular concern have been reconsidered in light of the trial's findings, part of a broader shift in how testosterone therapy is discussed clinically after years of the cardiovascular question dominating the conversation.

The TRAVERSE trial specifically addressed cardiovascular safety; it wasn't designed to comprehensively resolve every safety question around testosterone therapy, and monitoring for other known effects — including changes to red blood cell count that require periodic blood testing, and prostate health monitoring — remains a standard part of appropriately managed testosterone therapy regardless of the cardiovascular reassurance. More recent research has also flagged a narrower, more specific concern around minor complication rates following certain orthopedic procedures like knee replacement in men on active testosterone therapy, a detail relevant to that specific clinical context rather than to testosterone therapy broadly.

For men with symptoms suggestive of low testosterone — persistent fatigue, reduced libido, mood changes, or reduced muscle mass — pursuing a proper diagnostic workup with repeated morning testosterone measurements, rather than starting therapy based on symptoms alone or an online-only diagnosis, remains the appropriate first step; the TRAVERSE trial addressed a major cardiovascular safety concern for men who genuinely meet the clinical criteria, but it isn't a blanket endorsement for testosterone use outside documented, confirmed hypogonadism.